✦ LIBER ✦

[54] PEGINTERFERON-ALPHA-2a PLUS ADEFOVIR VS. PEGINTERFERON ALPHA-2a FOR 48 WEEKS IN HBeAg-NEGATIVE CHRONIC HEPATITIS B: PRELIMINARY 24-WEEK RESULTS OF THE PEG FOR B RANDOMIZED MULTICENTER TRIAL

✍ Scribed by P. Piccolo; I. Lend; D. Di Paolo; C. Telesca; L. DeMelia; O. Sorbello; F. Bandiera; M.R. Piras; G. Antonucci; F. lacomi; L. Nosotti; T. Mari; A. DeSantis; F. Cristofari; M.L. Ponti; M. Angelico

Book ID: 117375156
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 143 KB
Volume: 46
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(07)61652-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

43 A multicenter, randomized, open-label

43 A multicenter, randomized, open-label study of peginterferon alpha-2b vs interferon alpha-2b for the treatment of chinese patients with HBeAg+VE chronic hepatitis B

✍ H. Zhao; C.-W. Si; L. Wei; M.-B. Wan; Y.-K. Ying; J.-L. Hou; J.-Q. Niu; G.-Q. Wa 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 257 KB

52 A randomized trial of telbivudine (LD

52 A randomized trial of telbivudine (LDT) vs. adefovir for HBeAg-positive chronic hepatitis B: Results of the primary week 24 analysis

✍ H.L.Y. Chan; C.L. Lai; M. Cho; J. Heathcote; Y.-M. Moon; Y.-C. Chao; R. Myers; G 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 245 KB

PGI24 Cost-Effectiveness Analysis of 48-

PGI24 Cost-Effectiveness Analysis of 48-Week Peginterferon Alpha-2a Under RGT Strategy Versus 3 Years Entecavir for the Treatment of HBeAg-Positive Chronic Hepatitis B in China

✍ W. Zhang; H. Zhuang; H. Ren; X. Dou; W. Chen 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

A randomized trial of 24- vs. 48-week co

A randomized trial of 24- vs. 48-week courses of PEG interferon α-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan

✍ Ming-Lung Yu; Chia-Yen Dai; Zu-Yau Lin; Li-Po Lee; Nei-Jen Hou; Ming-Yen Hsieh; 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 136 KB

The results of a randomized trial lookin

The results of a randomized trial looking at 24 weeks vs 48 weeks of treatment with peginterferon α-2a (40 kDa) and ribavirin combination therapy in patients with chronic hepatitis C genotype 1

✍ C. Brandão; A. Barone; F. Carrilho; A. Silva; M. Patelli; C. Caramori; R. Focacc 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 160 KB

734 Peginterferon alpha-2a (PEGASYS) plu

734 Peginterferon alpha-2a (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks in patients with HCV genotype 2 OR 3. Final results of the accelerate trial

✍ M.L. Shiffman; S. Pappas; L. Nyberg; S. Greenbloom; A. Gibas; B. Bacons; J. Rase 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 124 KB